These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
360 related articles for article (PubMed ID: 34457214)
1. An overview of potential inhibitors targeting non-structural proteins 3 (PL Yan F; Gao F Comput Struct Biotechnol J; 2021; 19():4868-4883. PubMed ID: 34457214 [TBL] [Abstract][Full Text] [Related]
2. Targeting SARS-CoV-2 Nsp3 macrodomain structure with insights from human poly(ADP-ribose) glycohydrolase (PARG) structures with inhibitors. Brosey CA; Houl JH; Katsonis P; Balapiti-Modarage LPF; Bommagani S; Arvai A; Moiani D; Bacolla A; Link T; Warden LS; Lichtarge O; Jones DE; Ahmed Z; Tainer JA Prog Biophys Mol Biol; 2021 Aug; 163():171-186. PubMed ID: 33636189 [TBL] [Abstract][Full Text] [Related]
3. Current Strategies of Antiviral Drug Discovery for COVID-19. Mei M; Tan X Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887 [TBL] [Abstract][Full Text] [Related]
4. Macrodomain Mac1 of SARS-CoV-2 Nonstructural Protein 3 Hydrolyzes Diverse ADP-ribosylated Substrates. Chea C; Lee DY; Kato J; Ishiwata-Endo H; Moss J bioRxiv; 2023 Feb; ():. PubMed ID: 36945431 [TBL] [Abstract][Full Text] [Related]
9. Polyphenolic Compounds Isolated from Marine Algae Attenuate the Replication of SARS-CoV-2 in the Host Cell through a Multi-Target Approach of 3CL Nagahawatta DP; Liyanage NM; Je JG; Jayawardhana HHACK; Jayawardena TU; Jeong SH; Kwon HJ; Choi CS; Jeon YJ Mar Drugs; 2022 Dec; 20(12):. PubMed ID: 36547933 [TBL] [Abstract][Full Text] [Related]
10. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL Froggatt HM; Heaton BE; Heaton NS J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534 [TBL] [Abstract][Full Text] [Related]
11. Targeting novel structural and functional features of coronavirus protease nsp5 (3CL Roe MK; Junod NA; Young AR; Beachboard DC; Stobart CC J Gen Virol; 2021 Mar; 102(3):. PubMed ID: 33507143 [TBL] [Abstract][Full Text] [Related]
12. Discovery of highly potent covalent SARS-CoV-2 3CL Zhang FM; Huang T; Wang F; Zhang GS; Liu D; Dai J; Zhang JW; Li QH; Lin GQ; Gao D; Zhao J; Tian P Eur J Med Chem; 2023 Nov; 260():115721. PubMed ID: 37598484 [TBL] [Abstract][Full Text] [Related]
13. Spatial and temporal roles of SARS-CoV PL Yan S; Wu G FASEB J; 2021 Jan; 35(1):e21197. PubMed ID: 33368679 [TBL] [Abstract][Full Text] [Related]
14. Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease. Hajbabaie R; Harper MT; Rahman T Molecules; 2021 Feb; 26(4):. PubMed ID: 33672721 [TBL] [Abstract][Full Text] [Related]
15. An MHV macrodomain mutant predicted to lack ADP-ribose binding activity is severely attenuated, indicating multiple roles for the macrodomain in coronavirus replication. Voth LS; O'Connor JJ; Kerr CM; Doerger E; Schwarting N; Sperstad P; Johnson DK; Fehr AR bioRxiv; 2021 Mar; ():. PubMed ID: 33821264 [TBL] [Abstract][Full Text] [Related]
16. Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS. Tomar S; Johnston ML; St John SE; Osswald HL; Nyalapatla PR; Paul LN; Ghosh AK; Denison MR; Mesecar AD J Biol Chem; 2015 Aug; 290(32):19403-22. PubMed ID: 26055715 [TBL] [Abstract][Full Text] [Related]
17. Reprofiling of approved drugs against SARS-CoV-2 main protease: an in-silico study. Kumar P; Bhardwaj T; Kumar A; Gehi BR; Kapuganti SK; Garg N; Nath G; Giri R J Biomol Struct Dyn; 2022 Apr; 40(7):3170-3184. PubMed ID: 33179586 [TBL] [Abstract][Full Text] [Related]
18. Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors. He J; Hu L; Huang X; Wang C; Zhang Z; Wang Y; Zhang D; Ye W Int J Antimicrob Agents; 2020 Aug; 56(2):106055. PubMed ID: 32534187 [TBL] [Abstract][Full Text] [Related]
19. Identification of high-affinity inhibitors of SARS-CoV-2 main protease: Towards the development of effective COVID-19 therapy. Mohammad T; Shamsi A; Anwar S; Umair M; Hussain A; Rehman MT; AlAjmi MF; Islam A; Hassan MI Virus Res; 2020 Oct; 288():198102. PubMed ID: 32717346 [TBL] [Abstract][Full Text] [Related]
20. The SARS-CoV-2 main protease (M Hu Q; Xiong Y; Zhu GH; Zhang YN; Zhang YW; Huang P; Ge GB MedComm (2020); 2022 Sep; 3(3):e151. PubMed ID: 35845352 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]